US 11,753,457 B2
Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory T cells to treat autoimmune diseases
James Matthaei, South San Francisco, CA (US); Anne-Renee van der Vuurst de Vries, South San Francisco, CA (US); Joshua Beilke, South San Francisco, CA (US); Vivianne Malmström, Stockholm (SE); Kathryn Hooper, South San Francisco, CA (US); Rebecca Johnson, South San Francisco, CA (US); and Lars Klareskog, Stockholm (SE)
Assigned to Sonoma Biotherapeutics, Inc., South San Francisco, CA (US); and Curara AB, Stockholm (SE)
Filed by Sonoma Biotherapeutics, Inc., South San Francisco, CA (US); and Curara AB, Stockholm (SE)
Filed on Nov. 22, 2022, as Appl. No. 18/58,162.
Application 18/058,162 is a continuation of application No. PCT/US2022/074321, filed on Jul. 29, 2022.
Claims priority of provisional application 63/339,361, filed on May 6, 2022.
Claims priority of provisional application 63/227,320, filed on Jul. 29, 2021.
Prior Publication US 2023/0080155 A1, Mar. 16, 2023
Int. Cl. A61K 39/00 (2006.01); C07K 14/725 (2006.01); A61P 37/06 (2006.01); A61P 19/02 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 16/18 (2006.01); C07K 16/36 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/18 (2013.01); C07K 16/36 (2013.01); C12N 5/0636 (2013.01); C12N 15/625 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2317/622 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/998 (2013.01)] 30 Claims
 
1. A chimeric antigen receptor (CAR) comprising an antigen-binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains, and an intracellular signaling domain, wherein the antigen binding domain specifically binds to three or more different citrullinated proteins or citrullinated fragments thereof, and comprises complementarity-determining regions (CDRs) from VH and VL domains of SEQ ID NO:1 and SEQ ID NO:4.